All News

While biopharmaceutical companies are using websites and third-party postings to provide information on medical products - despite a host of regulatory issues - social media use is in its infancy related to the design and conduct of clinical trials.

Amid the looming March 31 deadline for remaining uninsured and underinsured Americans to purchase health insurance mandated by the Affordable Care Act (6 million newly Medicaid-eligible individuals are expected to enroll), pharmaceutical manufacturers and other key players in this space are emphasizing the importance of enhancing access to medications for the now rapidly expanding patient base.

As the U.S. heads towards a public market place in which Medicare, Medicaid, CHIPs, VA, and now Obamacare will shortly comprise almost 70% of the American healthcare market, American Rx marketers recently endured a “close call” with the U.S. Department of Health and Human Services over the arbitrary deletion of dozens of key drugs from a major American public Rx platform – Medicare Part D.

Japan’s schizophrenia treatment market value will see revenues doubling from $0.7 billion in 2012 to $1.4 billion by 2022 (a Compound Annual Growth Rate [CAGR] of 7.74%), says a new report from GlobalData.

Dr. Karen Midthun, director of FDA’s Center for Biologics Evaluation and Research, outlined the importance of the Department of Health and Human Services (HHS) National Vaccine Plan, in a FDA blog on March 11, 2014.

In an abrupt about-face, the Obama administration halted its ill-timed effort to launch an overhaul of the Medicare Part D program and announced it would not pursue changes in some key rules as proposed earlier this year.

The plan to accelerate generic pricing and reimbursement has become another tragic European casualty, writes Brussels correspondent Reflector.

Despite a slight boost in funding for the Food and Drug Administration and stronger tax incentives for investment in R&D, significant changes in Medicare drug reimbursement and coverage policies have biopharmaceutical companies up in arms.

The Asia-Pacific (APAC) region is experiencing a significant boom in the volume of private equity and venture capital investments in biotechnology.

Historically, pharmaceutical companies have leveraged remote patient monitoring (RPM) in a very limited way to improve data collection in clinical trials.

Interaction between pharma representatives and doctors has traditionally been a paper-based and static experience in which the representative enters with one-quarter of a campaign in hand and then tries to deliver the remaining pieces three more times through the year.

Just think what Frankenstein could do with this product. It looks like skin, feels like skin, but it’s not skin. It’s LabSkin, a facsimile, being manufactured by a clinical research group Venn Life Sciences.

A milestone of sorts took place on Monday March 3 when MarijuanaDoctors.com began airing a television commercial that looks to be the first ever marijuana commercial on a major TV network.

Despite recent legislation to establish a more secure pharmaceutical supply chain to deliver high quality, approved medicines to American patients, efforts to block the import of substandard, fraudulent, and counterfeit drugs remains an uphill fight.

Regardless of how you define it, partnership is also an institutional necessity as big Pharma adjusts to disruptive changes in the way health services are financed and delivered. A revolution in the making, where legislation combined with market forces as well as community and stakeholder advocacy are adding fresh momentum to a population-based approach to health practice. Population health focuses on a system built around three pillars of care: preventive care, primary care, and coordinated care, all driven by a single performance metric, which is value, as evidenced through quality and outcomes. Executing around this integrative model depends entirely on partnerships, especially with non-traditional players like the physician assistant.

Widespread screening, along with new therapies that move patients from a chronic condition to a cure, is changing the landscape in treatment of hepatitis C, says an expert panel recently convened by the American Journal of Managed Care (AJMC).

The Myelin Repair Foundation is more than just a policy precedent - it’s also emerging as the stimulus behind a future cure for MS.

While biosimilar products have been launched in Asia and Europe, they are at least three years away in the US, according to a new report on the global biosimilar drugs market.

When the Generic Drug User Fee Act (GDUFA) was signed into law on July 7, 2012, its primary intent was to provide FDA with the additional resources necessary to expedite the review process for generic drugs, and combat the agency’s backlog of drug applications.

Swedish Orphan Biovitrum AB (Sobi) was last night presented with a EURORDIS Award for its commercial and development portfolio in the field of rare diseases.

Bioscience research in China is set to overtake the United States within the next five to ten years, according to data from search engine CiteAb.

Not long ago, I was privy to a discussion taking place in a large drug development services company.

Following the U.S. ban on all imports from Ranbaxy’s Toansa, India, facility, the drug maker has voluntarily suspended all shipments of bulk drugs from its manufacturing facilities both at Toansa and Dewas, in order to reassess quality controls at the plants.

The latest news on the growing cost of conducting clinical trials is becoming a major concern for company sponsors and trial co-operative groups.

In less than a decade, online video marketing has moved from a standing start to become an essential part of the digital marketing mix

This week (February 28), Europe will celebrate Rare Disease Day. This is an interesting example – one might almost say a rare example – of a successful attempt by a European interest group to capture public attention.

Any pricing or revenue management initiative is only as good as the information on which it is based.

Europe’s main pharma industry bodies - EFPIA, EGA, EuropaBio, AESGP and EUCOPE - have issued a joint statement to express concern about “the increasing financial burden of regulatory costs incurred since the adoption of the pharmacovigilance package in 2010?.

In this short video, Brianna Cayo-Cotter, Change.org’s managing director of communications, talks to Pharm Exec about how advocacy organizations and individual patients are getting more involved in every facet of the healthcare system, from drug R&D, to federal and state policy, all fueled by the hour-to-hour passion of living with a disease.

Four class representatives have been added to a class-action gender-discrimination employment suit originally filed last May against Merck & Co. in New Jersey.